A 12-Month, open label, multi-center study to evaluate the efficacy and safety of intravitreal injections of Ranibizumab 0.5mg on cystoids, spongy and mixed Optical Coherence Tomography patterns secondary to Diabetic Macular Oedema (DME)
Latest Information Update: 12 Nov 2018
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Sponsors Novartis Healthcare
- 12 Nov 2018 New trial record